EIF2AK3 and breast carcinoma: To test the conjecture that GCN2 compensates for PERK inactivation and to explore further the mechanism for PERK regulation, we investigated the effects of the chemotherapeutic drugs on PERK and GCN2 signalling in the drug sensitive and resistant MCF-7 breast cancer cells.